IP Library Granted Patent US 7,547,535
Granted Patent B2
US 7,547,535 · App. 11/298,778 · Granted Jun 16, 2009

Forms of soluble pyrroloquinoline quinone-dependent glucose dehydrogenase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,547,535
App. No.
11/298,778
Granted
Jun 16, 2009
Kind
B2
Abstract

The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.

Claims (11)

1. A pyrroloquinoline quinone (PQQ)-dependent soluble glucose dehydrogenase (s-GDH) mutant, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 24 and wherein said mutant comprises an alanine or a serine substitution for threonine at position 348 of SEQ ID NO: 24 and wherein the mutant has s-GDH activity.

2. The mutant of claim 1 , wherein at least one amino acid residue selected from the group consisting of Gln 76 , Asp 143 , Gln 168 , Leu 169 , and Asn 428 , of SEQ ID NO: 24, is substituted with another amino acid.

3. The mutant of claim 1 , wherein the glutamine at position 76 of SEQ ID NO: 24 is substituted with a different amino acid.

4. The mutant of claim 1 wherein the asparagine at position 428 of SEQ ID NO: 24 is substituted with another amino acid.

5. The mutant of claim 4 , wherein at least one amino acid residue selected from the group consisting of Gln 76 , Thr 127 , and Asp 143 , of SEQ ID NO: 24, is substituted with a different amino acid.

6. The mutant of claim 4 , wherein at least one amino acid residue selected from the group consisting of Glu 245 and Met 341 , of SEQ ID NO: 24, is substituted with a different amino acid.

7. The mutant of claim 3 , wherein the glutamine at position 76, of SEQ ID NO: 24, is substituted with an amino acid selected from the group consisting of alanine, methionine, aspartic acid, proline, serine, glycine, and glutamic acid.

8. The mutant of claim 1 wherein amino acid residues other than glutamine and asparagine are present at positions 76 and 428, respectively, of SEQ ID NO: 24.

9. A PQQ-dependent s-GDH mutant, said mutant comprising an amino acid sequence at least 90% identical to SEQ ID NO: 24 wherein said mutant comprises a serine substitution for threonine at position 348 of SEQ ID NO: 24 and wherein the mutant has s-GDH activity.

10. A PQQ-dependent s-GDH mutant, said mutant comprising an amino acid sequence at least 90% identical to SEQ ID NO: 24 wherein said mutant comprises an alanine substitution for threonine at position 348 of SEQ ID NO: 24 and wherein the mutant has s-GDH activity.

11. The mutant of claim 1 further wherein tyrosine, glycine, and serine residues are substituted at positions 227, 348, and 438, respectively, of SEQ ID NO: 24.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2015
From: ROCHE DIAGNOSTICS OPERATIONS, INC.
To: ROCHE DIABETES CARE, INC.
Reel/Frame 036008/0670 →